EA201890161A1 - Терапевтические композиции, комбинации и способы применения - Google Patents
Терапевтические композиции, комбинации и способы примененияInfo
- Publication number
- EA201890161A1 EA201890161A1 EA201890161A EA201890161A EA201890161A1 EA 201890161 A1 EA201890161 A1 EA 201890161A1 EA 201890161 A EA201890161 A EA 201890161A EA 201890161 A EA201890161 A EA 201890161A EA 201890161 A1 EA201890161 A1 EA 201890161A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- combinations
- therapeutic compositions
- application methods
- methods
- mammals
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229940124783 FAK inhibitor Drugs 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Это изобретение относится к способам, включающим введение ингибитора FAK и иммунотерапевтического агента, такого как анти-PD-1 или анти-PD-L1; оно может быть использовано в лечении аномального роста клеток, такого как рак, у млекопитающих, особенно у человека.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562186197P | 2015-06-29 | 2015-06-29 | |
PCT/US2016/040080 WO2017004192A1 (en) | 2015-06-29 | 2016-06-29 | Therapeutic compositions, combinations, and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201890161A1 true EA201890161A1 (ru) | 2018-06-29 |
Family
ID=57609144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890161A EA201890161A1 (ru) | 2015-06-29 | 2016-06-29 | Терапевтические композиции, комбинации и способы применения |
Country Status (13)
Country | Link |
---|---|
US (3) | US10532056B2 (ru) |
EP (1) | EP3313404A4 (ru) |
JP (2) | JP2018519327A (ru) |
KR (1) | KR20180100539A (ru) |
CN (2) | CN114209841A (ru) |
AU (3) | AU2016286091B2 (ru) |
CA (1) | CA2991044A1 (ru) |
EA (1) | EA201890161A1 (ru) |
HK (1) | HK1254525A1 (ru) |
IL (1) | IL256652A (ru) |
MX (2) | MX2018000288A (ru) |
WO (1) | WO2017004192A1 (ru) |
ZA (1) | ZA201800572B (ru) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2724929T3 (es) | 2013-07-18 | 2019-09-17 | Taiho Pharmaceutical Co Ltd | Fármaco antitumoral para la administración intermitente de un inhibidor de FGFR |
EP3023101B1 (en) | 2013-07-18 | 2020-08-19 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for fgfr inhibitor-resistant cancer |
KR20170135860A (ko) | 2015-03-13 | 2017-12-08 | 싸이톰스 테라퓨틱스, 인크. | 항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법 |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
BR112018000768A2 (pt) | 2015-07-13 | 2018-09-25 | Cytomx Therapeutics Inc | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
EP3580569B1 (en) * | 2017-02-07 | 2022-03-09 | Saitama Medical University | Immunological biomarker for predicting clinical effect of cancer immunotherapy |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
WO2019018666A1 (en) * | 2017-07-21 | 2019-01-24 | University Of North Dakota | INHIBITION OF FAK-AKT INTERACTION TO INHIBIT METASTASES |
CA3093742A1 (en) * | 2018-03-12 | 2019-09-19 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers |
MA52093A (fr) | 2018-03-19 | 2021-01-27 | Taiho Pharmaceutical Co Ltd | Composition pharmaceutique comprenant du sulfate d'alkyle de sodium |
CN110960679A (zh) * | 2018-09-28 | 2020-04-07 | 江苏康缘药业股份有限公司 | 一种抗肿瘤的药物组合物及其应用 |
AU2019414550B2 (en) * | 2018-12-27 | 2022-09-22 | Hinova Pharmaceuticals Inc. | FAK inhibitor and drug combination thereof |
CN109675040B (zh) * | 2018-12-31 | 2021-07-30 | 清华大学 | 治疗乳腺癌的组合物及其应用 |
KR20210131387A (ko) * | 2019-02-28 | 2021-11-02 | 다이호야쿠힌고교 가부시키가이샤 | 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법 |
WO2020202005A1 (en) * | 2019-04-02 | 2020-10-08 | Inxmed (Shanghai) Co., Ltd. | Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors |
TWI757716B (zh) * | 2019-04-15 | 2022-03-11 | 禾榮科技股份有限公司 | 微創型中子束產生裝置及微創型中子捕獲治療系統 |
CN110201171A (zh) * | 2019-06-18 | 2019-09-06 | 北京大学 | Fak抑制剂在治疗常染色体显性遗传多囊肾病中的应用 |
CA3145889A1 (en) * | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
JP2022547358A (ja) * | 2019-09-13 | 2022-11-14 | ジ インスティテュート オブ キャンサー リサーチ:ロイヤル キャンサー ホスピタル | 治療組成物、組み合わせ、及び使用方法 |
AU2020388848A1 (en) * | 2019-11-18 | 2022-05-26 | Inxmed (Nanjing) Co., Ltd. | Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation |
MX2022006402A (es) * | 2019-11-28 | 2022-06-24 | Inxmed Nanjing Co Ltd | Uso de bi853520 en tratamiento contra el cancer. |
BR112022015161A2 (pt) * | 2020-01-31 | 2022-10-11 | Verastem Inc | Terapia de combinação para tratamento de crescimento celular anormal |
MX2022009612A (es) * | 2020-02-05 | 2022-09-19 | Inxmed Nanjing Co Ltd | Combinacion de bi853520 con farmacos quimioterapeuticos. |
IL303567A (en) * | 2020-12-08 | 2023-08-01 | Univ Cornell | Methods for inducing an immunomodulatory tumor response |
CN117015377A (zh) * | 2020-12-11 | 2023-11-07 | 材料治疗公司 | 使用波生坦与检查点抑制剂组合的癌症治疗 |
TW202313044A (zh) * | 2021-08-16 | 2023-04-01 | 大陸商應世生物科技(南京)有限公司 | In10018與pld的聯用 |
WO2023193705A1 (zh) * | 2022-04-07 | 2023-10-12 | 深圳微芯生物科技股份有限公司 | 西奥罗尼在抗胰腺癌中的用途 |
US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
WO2023246869A1 (zh) * | 2022-06-24 | 2023-12-28 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
WO2024051679A1 (zh) * | 2022-09-05 | 2024-03-14 | 应世生物科技(南京)有限公司 | Fak抑制剂及egfr-tki的药物组合及用途 |
WO2024056074A1 (zh) * | 2022-09-16 | 2024-03-21 | 应世生物科技(南京)有限公司 | Fak抑制剂及拓扑异构酶抑制剂的药物组合及用途 |
WO2024067631A1 (zh) * | 2022-09-30 | 2024-04-04 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
US20030009158A1 (en) | 2001-07-09 | 2003-01-09 | Perricone Nicholas V. | Skin treatments using blue and violet light |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
FI20030976A (fi) | 2003-06-30 | 2004-12-31 | M Real Oyj | Päällystetty pohjapaperi ja menetelmä päällystetyn pohjapaperin valmistamiseksi |
US20090022846A1 (en) | 2004-06-30 | 2009-01-22 | Helle Wittorff | Chewing Gum Comprising Flavor Emulsion |
DK2134689T3 (da) | 2007-03-16 | 2014-06-30 | Scripps Research Inst | Inhibitorer af fokal adhæsionskinase |
GEP20125581B (en) | 2007-04-18 | 2012-07-25 | Pfizer Prod Inc | Sulfonyl amide derivatives for treatment of abnormal cell growth |
EP2249650A4 (en) | 2008-02-19 | 2012-01-11 | Glaxosmithkline Llc | ANILINOPYRIDINE AS A FAK HEMMER |
CA2726508C (en) | 2008-06-17 | 2016-06-07 | Astrazeneca Ab | Pyridine compounds |
JO3067B1 (ar) | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
US20140155410A1 (en) | 2008-10-27 | 2014-06-05 | Glaxosmithkline Llc | Pyrazolylaminopyridines as inhibitors of fak |
WO2013003575A1 (en) | 2011-06-28 | 2013-01-03 | Glaxosmithkline Llc | Method of administration and treatment |
WO2014055913A1 (en) * | 2012-10-05 | 2014-04-10 | Cerulean Pharma Inc. | Treatment of cancer |
EP3060919A4 (en) * | 2013-10-25 | 2018-02-14 | Nodality, Inc. | Methods and compositions for immunomodulation |
HUE043042T2 (hu) | 2013-11-01 | 2019-07-29 | Pfizer | Vektorok prosztatához kapcsolódó antigének expressziójára |
FI3698790T3 (fi) * | 2014-02-07 | 2023-06-06 | Verastem Inc | Menetelmiä epänormaalin solukasvun hoitamiseksi |
WO2017201043A1 (en) | 2016-05-16 | 2017-11-23 | Concert Pharmaceuticals, Inc. | Combination therapy for treating cancer |
-
2016
- 2016-06-29 CN CN202111345764.0A patent/CN114209841A/zh active Pending
- 2016-06-29 WO PCT/US2016/040080 patent/WO2017004192A1/en active Application Filing
- 2016-06-29 EA EA201890161A patent/EA201890161A1/ru unknown
- 2016-06-29 KR KR1020187002706A patent/KR20180100539A/ko not_active Application Discontinuation
- 2016-06-29 US US15/738,999 patent/US10532056B2/en active Active
- 2016-06-29 AU AU2016286091A patent/AU2016286091B2/en active Active
- 2016-06-29 CN CN201680044292.6A patent/CN108289892B/zh active Active
- 2016-06-29 EP EP16818676.5A patent/EP3313404A4/en active Pending
- 2016-06-29 MX MX2018000288A patent/MX2018000288A/es unknown
- 2016-06-29 JP JP2017568200A patent/JP2018519327A/ja not_active Withdrawn
- 2016-06-29 CA CA2991044A patent/CA2991044A1/en active Pending
-
2017
- 2017-12-28 IL IL256652A patent/IL256652A/en unknown
-
2018
- 2018-01-08 MX MX2022001165A patent/MX2022001165A/es unknown
- 2018-01-26 ZA ZA2018/00572A patent/ZA201800572B/en unknown
- 2018-10-29 HK HK18113775.4A patent/HK1254525A1/zh unknown
-
2019
- 2019-11-25 US US16/694,384 patent/US11564927B2/en active Active
-
2021
- 2021-04-19 AU AU2021202379A patent/AU2021202379B2/en active Active
- 2021-09-03 JP JP2021143803A patent/JP2021183650A/ja active Pending
-
2022
- 2022-12-21 US US18/085,792 patent/US20240000790A1/en active Pending
-
2023
- 2023-08-09 AU AU2023214272A patent/AU2023214272A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN108289892A (zh) | 2018-07-17 |
CN108289892B (zh) | 2021-11-23 |
WO2017004192A1 (en) | 2017-01-05 |
IL256652A (en) | 2018-02-28 |
AU2023214272A1 (en) | 2023-08-31 |
MX2018000288A (es) | 2018-11-09 |
CA2991044A1 (en) | 2017-01-05 |
AU2021202379B2 (en) | 2023-05-11 |
JP2018519327A (ja) | 2018-07-19 |
HK1254525A1 (zh) | 2019-07-19 |
US20180177788A1 (en) | 2018-06-28 |
BR112017028519A2 (pt) | 2018-08-28 |
AU2021202379A1 (en) | 2021-05-13 |
MX2022001165A (es) | 2022-02-22 |
US11564927B2 (en) | 2023-01-31 |
JP2021183650A (ja) | 2021-12-02 |
US20240000790A1 (en) | 2024-01-04 |
AU2016286091A1 (en) | 2018-02-22 |
ZA201800572B (en) | 2023-12-20 |
US10532056B2 (en) | 2020-01-14 |
US20200330471A1 (en) | 2020-10-22 |
EP3313404A1 (en) | 2018-05-02 |
AU2016286091B2 (en) | 2021-02-04 |
CN114209841A (zh) | 2022-03-22 |
KR20180100539A (ko) | 2018-09-11 |
EP3313404A4 (en) | 2019-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890161A1 (ru) | Терапевтические композиции, комбинации и способы применения | |
CY1124013T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
CY1122581T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
CY1122148T1 (el) | Συνθεσεις που περιεχουν βακτηριακα στελεχη | |
CY1122344T1 (el) | Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων | |
EA202092590A1 (ru) | Пиридазиноны в качестве ингибиторов parp7 | |
EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
PH12017501483A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
EA201891202A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201891201A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890050A1 (ru) | Композиции, содержащие бактериальные штаммы | |
MX2018003936A (es) | Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones. | |
MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
EA201790170A1 (ru) | Терапевтические соединения-ингибиторы | |
EA201691845A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
EA201691844A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
EA201890810A1 (ru) | Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение | |
PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
MX2021008225A (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
EA201691896A1 (ru) | Соединения и способы их применения | |
EA202092691A1 (ru) | Соединения для устранения боли, композиции, содержащие их, и способы их применения |